EMA. Semaglutide (Kayshild): The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product Kayshild (semaglutide), intended for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH).
29 gennaio 2026
Leggi


